Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Arjan A van de Loosdrecht; Wolfgang Kern; Anna Porwit; Peter Valent; Sharham Kordasti; Eline Cremers; Canan Alhan; Carolien Duetz; Alan Dunlop; Willemijn Hobo; Frank Preijers; Orianne Wagner-Ballon; Nicolas Chapuis; Michaela Fontenay; Peter Bettelheim; Lisa Eidenschink-Brodersen; Patricia Font; Ulrika Johansson; Michael R Loken; Jeroen G Te Marvelde; Sergio Matarraz; Kiyoyuki Ogata; Uta Oelschlaegel; Alberto Orfao; Katherina Psarra; Dolores Subirá; Denise A Wells; Marie C Béné; Matteo G Della Porta; Kate Burbury; Frauke Bellos; Vincent H J van der Velden; Theresia M Westers; Leonie Saft; Robin Ireland

doi:10.1002/cyto.b.22044

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Cytometry B Clin Cytom. 2023 Jan;104(1):77-86. doi: 10.1002/cyto.b.22044. Epub 2021 Dec 13.

Authors

Arjan A van de Loosdrecht¹, Wolfgang Kern², Anna Porwit³, Peter Valent⁴, Sharham Kordasti⁵, Eline Cremers⁶, Canan Alhan¹, Carolien Duetz¹, Alan Dunlop⁷, Willemijn Hobo⁸, Frank Preijers⁸, Orianne Wagner-Ballon^{9

10}, Nicolas Chapuis^{11

12}, Michaela Fontenay^{11

12}, Peter Bettelheim¹³, Lisa Eidenschink-Brodersen¹⁴, Patricia Font¹⁵, Ulrika Johansson¹⁶, Michael R Loken¹⁴, Jeroen G Te Marvelde¹⁷, Sergio Matarraz¹⁸, Kiyoyuki Ogata¹⁹, Uta Oelschlaegel²⁰, Alberto Orfao¹⁸, Katherina Psarra²¹, Dolores Subirá²², Denise A Wells¹⁴, Marie C Béné²³, Matteo G Della Porta^{24

25}, Kate Burbury²⁶, Frauke Bellos², Vincent H J van der Velden¹⁷, Theresia M Westers¹, Leonie Saft²⁷, Robin Ireland²⁸

Affiliations

¹ Department of Hematology, Amsterdam UMC, location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
² MLL Munich Leukemia Laboratory, Munich, Germany.
³ Department of Clinical Sciences, Division of Oncology and Pathology, Faculty of Medicine, Lund University, Lund, Sweden.
⁴ Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
⁵ Comprehensive Cancer Centre, King's College London, London, UK.
⁶ Department of Internal Medicine, Division of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands.
⁷ Department of Haemato-Oncology, Royal Marsden Hospital, London, UK.
⁸ Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁹ Department of Hematology and Immunology, Assistance Publique-Hôpitaux de Paris, University Hospital Henri Mondor, Créteil, France.
¹⁰ Université Paris-Est Créteil, Inserm U955, Créteil, France.
¹¹ Laboratory of Hematology, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Centre-Université de Paris, Paris, France.
¹² Institut Cochin, Université de Paris, INSERM U1016, CNRS UMR 8104, Paris, France.
¹³ Department of Hematology, Ordensklinikum Linz, Elisabethinen, Linz, Austria.
¹⁴ HematoLogics, Inc., Seattle, Washington, USA.
¹⁵ Department of Hematology, Hospital General Universitario Gregorio Marañon - IiSGM, Madrid, Spain.
¹⁶ Laboratory Medicine, SI-HMDS, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
¹⁷ Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
¹⁸ Cancer Research Center (CIC/IBMCC-USAL/CSIC), Department of Medicine and Cytometry Service, University of Salamanca, Institute for Biomedical Research of Salamanca (IBSAL) and CIBERONC, Salamanca, Spain.
¹⁹ Metropolitan Research and Treatment Centre for Blood Disorders (MRTC Japan), Tokyo, Japan.
²⁰ Department of Internal Medicine, University Hospital Carl-Gustav-Carus TU Dresden, Dresden, Germany.
²¹ Department of Immunology - Histocompatibility, Evangelismos Hospital, Athens, Greece.
²² Department of Hematology, Flow Cytometry Unit, Hospital Universitario de Guadalajara, Guadalajara, Spain.
²³ Hematology Biology, Nantes University Hospital and CRCINA, Nantes, France.
²⁴ IRCCS Humanitas Research Hospital, Milan, Italy.
²⁵ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
²⁶ Department of Haematology, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Australia.
²⁷ Department of Clinical Pathology, Division of Hematopathology, Karolinska University Hospital and Institute, Stockholm, Sweden.
²⁸ Department of Haematology and SE-HMDS, King's College Hospital NHS Foundation Trust, London, UK.

PMID: 34897979
DOI: 10.1002/cyto.b.22044

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Keywords: ELN; consensus; flow cytometry; myelodysplastic syndromes; standardization.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Flow Cytometry
Humans
Myelodysplastic Syndromes* / diagnosis